Gouws Capital LLC lowered its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 32.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,100 shares of the medical research company’s stock after selling 2,000 shares during the period. Amgen makes up approximately 0.8% of Gouws Capital LLC’s investment portfolio, making the stock its 21st biggest holding. Gouws Capital LLC’s holdings in Amgen were worth $1,728,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Baird Financial Group Inc. lifted its holdings in Amgen by 1.6% during the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after buying an additional 5,496 shares in the last quarter. MW Advisory LLC bought a new position in Amgen in the second quarter worth approximately $1,054,000. Integrated Advisors Network LLC lifted its holdings in shares of Amgen by 50.5% in the 1st quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after buying an additional 6,356 shares during the period. KBC Group NV grew its position in shares of Amgen by 51.7% during the 2nd quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after buying an additional 130,497 shares in the last quarter. Finally, Nilsine Partners LLC bought a new stake in shares of Amgen in the second quarter valued at about $3,329,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen Stock Performance
Shares of NASDAQ:AMGN traded up $8.41 on Friday, hitting $415.85. 729,902 shares of the company were exchanged, compared to its average volume of 2,745,971. The firm has a market capitalization of $224.82 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 2.98 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The stock’s 50 day moving average price is $412.35 and its 200 day moving average price is $371.88.
Amgen Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen’s dividend payout ratio is presently 62.65%.
Insider Buying and Selling at Amgen
In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
AMGN has been the subject of several recent research reports. Wells Fargo & Company boosted their price target on shares of Amgen from $400.00 to $435.00 and gave the company an “equal weight” rating in a report on Friday, September 4th. Guggenheim boosted their target price on shares of Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a report on Monday, August 10th. Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 6th. UBS Group lifted their price objective on shares of Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Canaccord Genuity Group increased their target price on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $389.71.
View Our Latest Report on AMGN
Amgen News Roundup
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: An analyst upgrade helped drive buying interest in Amgen, with reports indicating the stock rose about 3% following the rating change. Amgen Stock Price Up 3% on Analyst Upgrade
- Positive Sentiment: Cantor Fitzgerald raised its price target for AMGN from $400 to $440, signaling greater confidence in Amgen’s earnings outlook and pipeline prospects. The target increase is a notable bullish catalyst, though it still leaves limited upside if shares remain near recent levels. Cantor Fitzgerald Raises Amgen Price Target
- Positive Sentiment: Amgen announced a head-to-head Phase 3 trial of its monthly diabetes treatment against semaglutide. Success could give the company a significant opportunity in the competitive GLP-1 market and provide a longer-term growth catalyst. Amgen Diabetes Drug Phase 3 Trial
- Positive Sentiment: The company also reported results from a Sjögren’s syndrome trial and participated in a $30 million Series A investment in AI-based genetic testing, potentially strengthening its research and precision-medicine capabilities. Amgen AI Genetic Testing Investment
- Neutral Sentiment: Morgan Stanley maintained a Hold rating, while its price target was reduced slightly from $362 to $359. This provides a counterpoint to Cantor Fitzgerald’s bullish view and suggests analyst opinion remains divided. Morgan Stanley Hold Rating on Amgen
Amgen Profile
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.
Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.
Read More
- Five stocks we like better than Amgen
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
